Ipsen's IQIRVO Shows Strong Real-World Efficacy in PBC Treatment

Event summary

  • Ipsen presented late-breaking data at EASL 2026 showing IQIRVO® significantly reduced ALP levels and improved fatigue and pruritus in PBC patients.
  • Real-world analysis showed 59% of patients achieved ALP normalization at 6 months.
  • Interim Phase IV ELFINITY study data demonstrated rapid and sustained ALP reductions and symptom improvements within 3 months.
  • IQIRVO® is the only second-line PBC treatment providing both biochemical and symptom control.

The big picture

Ipsen's IQIRVO® is positioning itself as a key player in the PBC treatment landscape, addressing both biochemical markers and debilitating symptoms. The real-world data reinforces its potential to become a standard second-line therapy, which could significantly expand its market reach. The drug's unique mechanism of action and rapid efficacy provide a competitive edge in a niche but growing rare disease market.

What we're watching

Regulatory Verification
Whether IQIRVO® can sustain its clinical benefits to meet FDA and EMA post-approval requirements.
Market Expansion
The pace at which Ipsen can expand IQIRVO®'s approvals globally beyond the current 15 countries.
Competitive Positioning
How IQIRVO®'s dual biochemical and symptom control differentiates it from existing PBC treatments.